First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.

导出 OA

翻译打印收藏纠错

第一作者： Eric,Angevin

第一单位： Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, France.

作者： Eric,Angevin ^[1] ; Nicolas,Isambert ^[2] ; Véronique,Trillet-Lenoir ^[3] ; Benoit,You ^[3] ; Jérôme,Alexandre ^[4] ; Gérard,Zalcman ^[5] ; Philippe,Vielh ^[6] ; Françoise,Farace ^[6] ; Fanny,Valleix ^[7] ; Thomas,Podoll ^[8] ; Yu,Kuramochi ^[9] ; Itaru,Miyashita ^[9] ; Osamu,Hosono ^[10] ; Nam H,Dang ^[11] ; Kei,Ohnuma ^[12] ; Taketo,Yamada ^[13] ; Yutaro,Kaneko ^[14] ; Chikao,Morimoto ^[15]

作者单位： Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, France. ^[1] Centre Georges-François Leclerc, Unité de Phases Précoces, Dijon, France. ^[2] Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Lyon, France. ^[3] Hôpital Cochin, Paris, France. ^[4] Centre Hospitalier Universitaire (CHU) de Caen, Centre de Recherche Clinique/Essais de phases précoces, Caen, France. ^[5] Gustave Roussy, Translational Research Laboratory, Villejuif, France. ^[6] FV Clinical subcontractor for SynteractHCR SAS, Levallois-Perret, France. ^[7] Y's therapeutics Inc., Redwood City, CA, USA. ^[8] Kissei Pharmaceutical Co., Ltd, Tokyo, Japan. ^[9] Department of Rheumatology and Allergy, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. ^[10] Division of Hematology/Oncology, University of Florida, Gainesville, FL, USA. ^[11] Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan. ^[12] Keio University School of Medicine, Tokyo, Japan. ^[13] Saitama Medical University, Saitama, Japan. ^[14] Y's AC Co., Ltd, Tokyo, Japan. ^[15]